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Small-cell lung cancer (SCLC) is a particularly aggressive form of lung cancer characterized by rapid doubling time, high growth fraction, and early dissemination \[[@B1]\]. The staging system for the disease incorporates a binary classification: limited-stage SCLC is confined to one hemithorax while all other disease is categorized as extensive-stage SCLC \[[@B2]\]. Typically radio- and chemosensitive at the outset, the development of resistance even after initial response is practically a fait accompli for extensive-stage SCLC, usually within the first year from diagnosis \[[@B3]\]. The predicted probability of the efficacy of second-line chemotherapy is based on response to first-line treatment; 'sensitive' disease, that is relapse beyond 60 or 90 days after completion of first-line treatment, is associated with a better prognosis and survival outcome than 'refractory' disease, that is no response or relapse during ongoing first-line treatment, and 'resistant' disease, that is progression within 60 or 90 days following first-line response \[[@B4]\].

The topoisomerase I inhibitor topotecan is approved in the United States and European Union *only* for second-line therapy of sensitive SCLC \[[@B5]\], while the synthetic anthracycline amrubicin is approved in Japan \[[@B6]\]. For refractory or resistant SCLC, no standard therapy is available. The overall survival with topotecan in the resistant/refractory population ranges from 4.7 to 5.7 months \[[@B7]\] while the response rate is \<10% \[[@B8]\]. In addition to topotecan and amrubicin, cyclophosphamide, Adriamycin and vincristine (CAV) has been investigated with similarly poor overall survival, progression-free survival and response rates \[[@B9]\]. RRx-001 is a first-in-class systemically non-toxic \[[@B10]\] epi-immunotherapeutic agent \[[@B11]\] which possesses both radiosensitizing and chemosensitizing activity as well as radioprotective and chemoprotective properties \[[@B12],[@B13]\]; the molecule is under investigation as a tumor priming agent in an open-label phase II clinical trial called TRIPLE THREAT (NCT02489903), which involves treatment of SCLC, non-small-cell lung cancer (NSCLC) or platinum-refractory neuroendocrine tumors with RRx-001 until progression followed by sequential re-introduction of cisplatin or carboplatin and etoposide. In this report, the case of 77-year-old Caucasian male with extensive-stage refractory SCLC - so categorized because he initially relapsed during ongoing first-line treatment - who responded to retreatment with carboplatin/etoposide after progression on RRx-001 monotherapy is presented.

Case Presentation {#sec1_2}
=================

A 77-year-old Caucasian male with a 30-pack-year smoking history was diagnosed with a medically operable stage 1 NSCLC (squamous cell carcinoma) in 2000 and 2007, resulting in left upper and right upper lobectomies. In 2009 a CT revealed a new pulmonary nodule for which he received radiation and 7 cycles of adjuvant carboplatin and taxol. In 2015 a new mass on CT scan, biopsied with fine needle aspiration and fiberoptic bronchoscopy, established a histological diagnosis of SCLC.

In May and July 2015 the patient completed 4 cycles of cisplatin-etoposide with response assessment every 2 cycles or 6 weeks. Despite a partial radiographic response at week 6, disease progression was observed on therapy during cycle 4 (week 12), which classified his disease as refractory. In November 2015 he was enrolled on the TRIPLE THREAT clinical trial and began weekly intravenous treatment with RRx-001. However, despite a marked symptomatic improvement, a restaging scan at week 6 demonstrated disease progression per RECIST v.1.1 which was suspicious for pseudoprogression \[[@B14]\], given the association of RRx-001 with transient tumor enlargement during initial scans followed by stabilization or shrinkage.

Nevertheless, on the basis of RECIST-defined progression, he was restarted on platinum doublets (carboplatin/etoposide) in December 2015. After 2 cycles of doublet therapy (week 6), which was much better tolerated on this occasion than the first time he received it, a CT scan demonstrated around 30% tumor shrinkage, which met the criteria for a partial response. By week 12 (4 cycles) he developed neutropenia and therapy was interrupted. However, the restaging scan demonstrated a 58% reduction in the size of his tumors, confirming the partial response (fig. [1](#F1){ref-type="fig"}).
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In the pantheon of the most difficult to treat metastatic malignancies, SCLC is on par with ovarian, brain, liver and pancreatic cancer in terms of its multidrug resistance \[[@B15]\] and consequent intractability to second-line therapies, including so-called targeted agents. Stagnant for more than three decades, the standard treatment for extensive-stage SCLC remains cisplatin and etoposide (PE); the exquisite initial chemosensitivity to PE belies the very poor prognosis after treatment with subsequent therapies. Even though PD-1 checkpoint inhibitors may be poised to challenge the platinum hegemony and change the treatment landscape in SCLC as in NSCLC, the response rates to pembrolizumab in the phase Ib KEYNOTE-028 trial \[[@B16]\] as well as nivolumab and nivolumab/ipilimumab in the phase I/II CheckMate 032 trial are counterbalanced by concerns about increased autoimmune toxicities \[[@B17]\], given the association between SCLC and paraneoplastic disorders such as Lambert-Eaton myasthenic syndrome.

A key oncologic treatment goal is to reverse the inevitable death trajectory of metastatic tumors to one of long-term survival while minimizing adverse effects. The promising strategy of episensitization \[[@B18],[@B19]\], a hybrid term coined by Oronsky, Carter, Scicinski and Reid, which involves priming with a systemically non-toxic epigenetic agent like RRx-001 followed by rechallenge with formerly tried chemotherapies, represents a literal comeback both for the patient if the strategy is successful and the re-introduced first-line treatment. To date, 2 out of 3 resistant/refractory SCLC patients enrolled in the TRIPLE THREAT trial have demonstrated responses to re-introduced platinum doublets, suggesting that the episensitization strategy may have the potential to yield promising clinical benefits.
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![CT scan images showing tumor shrinkage after re-exposure to platinum doublets. Left: At disease progression on the study drug RRx-001, prior to re-introduction of platinum (12/30/2015). Right: After 4 cycles of platinum therapy (carboplatin/etoposide) (4/6/2016). Upper row: Decrease in size of the paratracheal lesion from 3.23 to 1.67 cm (-48%). Middle row: Disappearance of the right upper lobe lymph node lesion. Lower row: Decrease in size of the subtracheal lesion from 5.34 to 1.92 cm (-64%).](cro-0009-0285-g01){#F1}
